Suppressive signals in colorectal cancer: RasGRP1 a new marker for anti-EGFR therapy?. Read more about Suppressive signals in colorectal cancer: RasGRP1 a new marker for anti-EGFR therapy?.
Discrimination and quality of life among breast cancer survivors. Read more about Discrimination and quality of life among breast cancer survivors.
Patient utilization of supportive care services identified through the Athena Breast Health Questionnaire System. Read more about Patient utilization of supportive care services identified through the Athena Breast Health Questionnaire System.
Integrating outpatient palliative care into a metastatic breast oncology clinic. Read more about Integrating outpatient palliative care into a metastatic breast oncology clinic.
Role of pazopanib (PZ) in modulating hormone resistance in advanced breast cancer (ABC). Read more about Role of pazopanib (PZ) in modulating hormone resistance in advanced breast cancer (ABC).
Intestinal obstruction in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS). Read more about Intestinal obstruction in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).
Results of a first-in-human, phase I/II trial of ASP2215, a selective, potent inhibitor of FLT3/Axl in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). Read more about Results of a first-in-human, phase I/II trial of ASP2215, a selective, potent inhibitor of FLT3/Axl in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML).
FPA144, a humanized monoclonal antibody for both FGFR2 -amplified and nonamplified, FGFR2b -overexpressing gastric cancer patients. Read more about FPA144, a humanized monoclonal antibody for both FGFR2 -amplified and nonamplified, FGFR2b -overexpressing gastric cancer patients.
Clinical features, outcomes, and prognostic factors in patients with extraskeletal osteosarcoma. Read more about Clinical features, outcomes, and prognostic factors in patients with extraskeletal osteosarcoma.
Impact of comorbidity and age on survival among older veterans with early stage non-small cell lung cancer (NSCLC). Read more about Impact of comorbidity and age on survival among older veterans with early stage non-small cell lung cancer (NSCLC).
